Trials / Not Yet Recruiting
Not Yet RecruitingNCT06702098
Induced Pluripotent Stem Cells Derived Natural Killer Cells Therapy for Refractory and Relaps Acute Myelogenous Leukemia
Single-center and Single-arm Clinical Study of INK Cell Therapy for Relapsed and Refractory Acute Myeloid Leukemia
- Status
- Not Yet Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Guangzhou Ruixin Biotechnological Co., LTD · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
This is a clinical study on the use of iNK cells for the treatment of refractory relapsed acute myeloid leukemia.
Detailed description
Natural killer (NK) cells are lymphocytes of the innate immune system and could recognize and kill a wide range of cells in distress, particularly tumour cells and cells infected with viruses. Induced pluripotent setm cells(iPSCs) derived NK cells have better proliferative capacity and homogeneity than donor peripheral blood or umbilical cord blood derived NK cells. We conduct this clinical study to evaluate the efficacy and safety of INK cells in the treatment of acute myeloid leukemia and our purpose is to find new treatment option.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | iNK cells | Induced pluripotent stem cells derived NK cells. |
Timeline
- Start date
- 2024-11-25
- Primary completion
- 2026-08-31
- Completion
- 2026-11-24
- First posted
- 2024-11-22
- Last updated
- 2024-11-22
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06702098. Inclusion in this directory is not an endorsement.